The mechanism of SOS1’s anti-CML effect as identified using LC-MS/MS and RNA-seq is that the low regulation of SOS1 promotes expression of SLC22A4 in CML cells. Here, SLC22A4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.